FdaApplication
NDA 204370
Identifiers
- fda_app_no: NDA204370
Properties
| Property | Value |
|---|---|
| applicant_name | ABBVIE INC |
| application_type | NDA |
| approval_date | 2015-09-17 |
Revenue by product
VRAYLAR
| Period | Revenue |
|---|---|
| Q2 2026 | $1.1B |
| Q1 2026 | $905.0M |
| Q4 2025 | $1.0B |
| Q3 2025 | $934.0M |
| Q2 2025 | $900.0M |
| Q1 2025 | $765.0M |
| Q4 2024 | $924.0M |
| Q3 2024 | $875.0M |
| Q2 2024 | $774.0M |
| Q1 2024 | $694.0M |
| Q4 2023 | $789.0M |
| Q3 2023 | $751.0M |
| Q2 2023 | $658.0M |
| Q1 2023 | $561.0M |
| Q4 2022 | $565.0M |
| Q3 2022 | $554.0M |
| Q2 2022 | $492.0M |
| Q1 2022 | $427.0M |
| Q4 2021 | $489.0M |
| Q3 2021 | $461.0M |
| Q2 2021 | $432.0M |
| Q1 2021 | $346.0M |
| Q4 2020 | $401.0M |
| Q3 2020 | $358.0M |
| Q2 2020 | $192.0M |
| Q1 2020 | $0.0M |
| Q4 2019 | $0.0M |
| Q3 2019 | $0.0M |
| Q2 2019 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (6)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VRAYLAR | CARIPRAZINE HYDROCHLORIDE | EQ 4.5MG BASE | CAPSULE;ORAL |
| VRAYLAR | CARIPRAZINE HYDROCHLORIDE | EQ 6MG BASE | CAPSULE;ORAL |
| VRAYLAR | CARIPRAZINE HYDROCHLORIDE | EQ 1.5MG BASE | CAPSULE;ORAL |
| VRAYLAR | CARIPRAZINE HYDROCHLORIDE | EQ 0.5MG BASE | CAPSULE;ORAL |
| VRAYLAR | CARIPRAZINE HYDROCHLORIDE | EQ 3MG BASE | CAPSULE;ORAL |
| VRAYLAR | CARIPRAZINE HYDROCHLORIDE | EQ 0.75MG BASE | CAPSULE;ORAL |
6 products